Shanghai Xinshi Biomedical

Shanghai Xinshi Biomedical is a clinical-stage biotechnology company specializing in the development of next-generation "off-the-shelf" cell therapies using induced pluripotent stem cell (iPSC) technology. The company focuses on creating standardized, scalable immune cell products, such as iPSC-derived NK cells (iNK) and T cells (iT), to address the challenges of treating solid tumors. Their proprietary platform aims to significantly reduce the cost and manufacturing complexity associated with traditional autologous CAR-T therapies while improving therapeutic efficacy and persistence. Xinshi's pipeline includes several innovative candidates targeting high-prevalence cancers like liver and gastric malignancies. Based in Shanghai's Zhangjiang Hi-Tech Park, the company is led by a team of experts in stem cell biology and immunology dedicated to advancing regenerative medicine.